|

CRN09682 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Crinetics Pharmaceuticals Inc.1

Indications

  • SST2-positive Neuroendocrine Neoplasms1
  • Neuroendocrine Neoplasm1
  • Neuroendocrine Tumors1
  • Cancer1

Phoenix, Arizona1 trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Crinetics Study Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.